Eucrates Biomedical Acqui... (EUCRU)
NASDAQ: EUCRU
· Real-Time Price · USD
10.02
-0.07 (-0.69%)
At close: Apr 26, 2023, 9:59 PM
Company Description
Eucrates Biomedical Acquisition Corp. does not have significant operations.
The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe.
The company was incorporated in 2020 and is based in New York, New York.
Eucrates Biomedical Acquisition Corp.
| Country | United States |
| IPO Date | Oct 6, 2020 |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | n/a |
| CEO | Parag Phoolchand Saxena MBA, MS |
Contact Details
Address: 250 West 55th Street New York City, New York United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | EUCRU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001822929 |
| CUSIP Number | G3141W114 |
| ISIN Number | VGG3141W1142 |
| Employer ID | 00-0000000 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Parag Phoolchand Saxena MBA, MS | Chief Executive Officer & Director |
| Dr. Evangelos Vergetis | Pres, Chief Operating Officer & Director |
| Gonzalo Cordova CFA | Chief Financial Officer |
| Shrikant Sathe | Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 08, 2023 | 15-12G | Filing |
| Apr 26, 2023 | 25-NSE | Filing |
| Apr 13, 2023 | 10-K | Annual Report |
| Apr 11, 2023 | 8-K | Current Report |
| Apr 03, 2023 | 8-K | Current Report |
| Mar 29, 2023 | NT 10-K | Filing |
| Feb 16, 2023 | 8-K | Current Report |
| Feb 10, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2022 | 10-Q | Quarterly Report |
| Nov 09, 2022 | SC 13G | Statement of acquisition of beneficial ownership b... |